Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

Monday, July 5, 2021 1 min read

Key Takeaway: Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

Full Press Release Details

Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC.